Johnson & Johnson's (JNJ) Wins $1.67B Patent Verdict Versus Abbott Laboratories (ABT)
Up)
Centocor Ortho Biotech Inc., wholly-owned subsidiary of Johnson & Johnson (NYSE: JNJ), announced that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories (NYSE: ABT) in a patent infringement suit.
The patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee.
The patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee.
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- Proctor & Gamble (PG) To Change 'Tide Pods' Design So Kids Don't Eat Them
- Bazaarvoice (BV) Agrees to Buy PowerReviews; Offers Prelim. Q1 Results, Guides Q2, FY13
Create E-mail Alert Related Categories
Corporate News, Hot ListRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
